<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Respiratory bronchiolitis-associated interstitial lung disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Respiratory bronchiolitis-associated interstitial lung disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Respiratory bronchiolitis-associated interstitial lung disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) is categorized as a smoking-related interstitial pneumonia and is one of the idiopathic interstitial pneumonias (IIPs) [<a href="#rid1">1</a>]. The other major IIPs include idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP; another smoking-related IIP), acute interstitial pneumonia (AIP), and cryptogenic organizing pneumonia (COP).</p><p>The clinical presentation, diagnosis, treatment, and prognosis of RB-ILD will be reviewed here. The evaluation and diagnosis of ILD (including IIP) and bronchiolitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a> and  <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/z/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">"Acute interstitial pneumonia (Hamman-Rich syndrome)"</a> and  <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">"Lymphoid interstitial pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a>.)</p><p class="headingAnchor" id="H344100925"><span class="h1">DEFINITION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory bronchiolitis</strong> – Respiratory (or "smoker's") bronchiolitis (RB) is a well-recognized pathologic lesion found in the lungs of cigarette smokers that is generally not associated with respiratory symptoms. The key histopathologic features of RB are the presence of tan-pigmented macrophages (also known as smokers' macrophages) in the respiratory bronchioles, a patchy submucosal and peribronchiolar infiltrate of lymphocytes and histiocytes, and peribronchiolar fibrosis that extends into contiguous alveolar walls. (See <a class="local">'Histopathology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory bronchiolitis-interstitial lung disease</strong> – RB-ILD is defined by the presence of changes of RB as the sole pathologic finding in a current or former cigarette smoker with clinical evidence of ILD [<a href="#rid1">1-8</a>]. The degree to which fibrosis extends into the alveolar wall has sometimes been used to distinguish RB from RB-ILD, but most pathologists believe that the two processes cannot be distinguished on pathologic grounds alone [<a href="#rid2">2,9-12</a>]. Thus, RB-ILD probably represents a subset of individuals with a more severe stage in the spectrum of RB and is much less common than RB.</p><p></p><p class="headingAnchor" id="H1996764888"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>RB is a common histopathologic finding among smokers [<a href="#rid2">2</a>]; RB-ILD is uncommon, but the exact incidence is not known. </p><p>RB is often identified in cigarette smokers who undergo lung biopsy for another reason. In a series of 79 smokers with spontaneous pneumothorax requiring surgical intervention, RB was found in 70 (89 percent) lung biopsies [<a href="#rid13">13</a>]. Associated emphysematous lesions or desquamative interstitial pneumonitis were noted in approximately half of the patients with RB. Histopathologic assessment of lung tissue from a cohort of patients who underwent surgical resection for suspicious lung nodules/masses (89 percent were ever-smokers) identified radiographic pattern RB-ILD in 3.1 percent and histopathologic RB in 12.8 percent of these subjects, respectively [<a href="#rid14">14</a>].</p><p>Other estimates are based on the relative frequency of RB-ILD among patients with idiopathic interstitial pneumonias (IIPs) [<a href="#rid15">15-21</a>]. In a review of 168 lung biopsies performed for suspicion of idiopathic pulmonary fibrosis, 10 were RB-ILD [<a href="#rid15">15</a>]. In reviews of series from individual countries, RB-ILD was specifically identified in approximately 2 to 13 percent of cases of IIP [<a href="#rid17">17,20</a>]. In a study from Greece, the incidence of RB-ILD was estimated to be 0.04 per 100,000 [<a href="#rid19">19</a>]. (See <a class="local">'Histopathology'</a> below and  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a>.)</p><p class="headingAnchor" id="H344100678"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The exact pathogenesis of RB-ILD is unknown, although almost all patients with RB-ILD are current or former cigarette smokers, suggesting a key etiologic role of cigarette smoking. The role of cigarette smoking is supported by the improvement in disease manifestations that often accompanies smoking cessation. In addition, radiologic studies suggest a relationship between the duration and intensity of cigarette smoking and the presence on chest radiographs of the small irregular opacities (so-called "dirty lungs") associated with RB and RB-ILD [<a href="#rid22">22-25</a>].</p><p>Histopathologically, a lack of fibroblastic foci and bronchiolocentric distribution strongly differentiates RB-ILD from usual interstitial pneumonia, the pattern seen in interstitial pulmonary fibrosis. These differences suggest distinct underlying pathologic processes. In contrast, desquamative interstitial pneumonitis (DIP), which is highly associated with cigarette smoking, has similar pathologic changes to RB-ILD and may share a common pathogenesis. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'</a> and  <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">"Pathogenesis of idiopathic pulmonary fibrosis", section on 'Mechanisms of fibrosis'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Virtually all patients with RB-ILD are current or former cigarette smokers (&gt;30 pack years) [<a href="#rid2">2,3,15</a>]. Rarely, patients have been reported who have substantial passive cigarette smoke exposure or heavy use of electronic cigarettes (vaping) [<a href="#rid26">26-28</a>].</p><p>Patients typically present in their 30s to 50s with subacute symptoms of dyspnea (94 percent), wheeze (69 percent), cough (66 percent), and/or sputum production (50 percent)  (<a class="graphic graphic_figure graphicRef67993" href="/z/d/graphic/67993.html" rel="external">figure 1</a>) [<a href="#rid29">29</a>]. Pneumothorax, hemoptysis, and acute respiratory failure are less common initial manifestations [<a href="#rid13">13,30,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults"</a>.)</p><p>Fine, bibasilar end-inspiratory crackles are common findings (40 to 70 percent) on chest examination [<a href="#rid29">29,32</a>]. The crackles are described as being more coarse than those heard in other ILDs, such as idiopathic pulmonary fibrosis; they occur throughout inspiration and sometimes continue into expiration. Clubbing of the digits is unusual but has been reported in a small number of patients with RB-ILD [<a href="#rid29">29,33</a>]. (See  <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p class="headingAnchor" id="H344100401"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>RB-ILD is typically suspected when a current or recent cigarette smoker presents with nonspecific respiratory symptoms, such as dyspnea or cough, and has an abnormal chest radiograph. The most important diagnostic (and therapeutic) step is cessation of cigarette smoking and avoiding exposure to cigarette smoke. </p><p class="headingAnchor" id="H3"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Routine laboratory studies are nonspecific in RB-ILD and are more helpful in excluding alternative diagnoses than in making a diagnosis of RB-ILD. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Laboratory tests'</a>.)</p><p>An alpha-1 antitrypsin (AAT) level is commonly obtained in cigarette smokers with progressive dyspnea to exclude AAT deficiency. Other testing for rheumatic disease or hypersensitivity pneumonitis depends on the presence of extrapulmonary clinical findings suggestive of rheumatic disease and a history of occupational or other exposures that might cause hypersensitivity pneumonitis. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency", section on 'Evaluation and diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis", section on 'Laboratory tests'</a>.)</p><p class="headingAnchor" id="H344100865"><span class="h2">Pulmonary function tests</span><span class="headingEndMark"> — </span>Pulmonary function tests (PFTs) are obtained to ascertain the pattern and magnitude of ventilatory impairment. The most common PFT finding in RB-ILD is a mixed obstructive-restrictive pattern with mild to moderate reduction in diffusing capacity for carbon monoxide (DLCO) [<a href="#rid1">1,32</a>]. The mixture of obstructive and restrictive patterns is attributed to the airway inflammation from heavy cigarette smoke exposure, which causes obstructive physiology, and the interstitial disease associated with RB-ILD, which causes restriction and a gas transfer abnormality. Occasionally, an isolated increase in residual volume (ie, mild air trapping) is noted. (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>Few studies of gas exchange in RB-ILD have been reported. In a series of 10 patients with RB-ILD, the DLCO was moderately reduced (mean 57 percent of predicted) in eight patients in association with abnormalities in spirometry or lung volume [<a href="#rid32">32</a>]. One patient had a reduced DLCO without other PFT abnormalities and one had completely normal PFTs. (See  <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a> and  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Diffusing capacity'</a>.)</p><p>Pulse oximetry is mildly reduced at rest or with exercise in most patients, but may occasionally be severely reduced [<a href="#rid29">29,32-34</a>]. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Gas exchange at rest and on exertion'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Chest radiographs are usually obtained to evaluate dyspnea or cough in a cigarette smoker. The chest radiograph in RB-ILD often demonstrates diffuse, fine reticular or nodular opacities with preserved lung volumes  (<a class="graphic graphic_diagnosticimage graphicRef59288" href="/z/d/graphic/59288.html" rel="external">image 1</a>), although the plain radiograph is normal in up to 28 percent [<a href="#rid32">32,35</a>]. Bronchial wall thickening, prominence of the peribronchovascular markings, small regular and irregular opacities, and small peripheral ring shadows are other common features of RB-ILD [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/6979.html" rel="external">"Evaluation of diffuse lung disease by conventional chest radiography", section on 'Basic patterns'</a>.)</p><p>High-resolution computed tomography (HRCT) findings are nonspecific and include diffuse or patchy ground-glass opacities, centrilobular nodules, and air trapping  (<a class="graphic graphic_diagnosticimage graphicRef68487" href="/z/d/graphic/68487.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef82553" href="/z/d/graphic/82553.html" rel="external">image 3</a>) [<a href="#rid1">1,35,37-40</a>]. In a series of 21 patients, HRCT findings included central bronchial wall thickening (90 percent), peripheral bronchial wall thickening (86 percent), centrilobular nodules (71 percent), and ground-glass opacity (67 percent). Ill-defined centrilobular nodules with upper lung zone predominance and without tree-in-bud opacities were noted in five patients with RB-ILD [<a href="#rid39">39</a>].</p><p>Centrilobular emphysema is reported in 57 percent of patients with RB-ILD, usually in the upper lung zones; septal lines and a reticular pattern are noted in 33 percent [<a href="#rid29">29,35</a>]. Atelectasis, intralobular lines, interlobular septal thickening, and peripheral blebs have been reported less commonly. (See  <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs", section on 'HRCT patterns'</a> and <a class="local">'Differential diagnosis'</a> below.)</p><p>Ground-glass nodules may be seen on HRCT scans of asymptomatic smokers due to RB, so this finding does not necessarily imply RB-ILD in the absence of symptomatic or physiologic impairment.</p><p class="headingAnchor" id="H344100884"><span class="h2">Bronchoscopy</span><span class="headingEndMark"> — </span>Bronchoscopy with bronchoalveolar lavage (BAL) is typically reserved for patients with diagnostic uncertainty in the setting of moderate to severe disease on the basis of symptoms, pulmonary function impairment, or imaging or progressive disease despite smoking cessation. For patients with mild disease, it is reasonable to await a response to smoking cessation before proceeding with BAL. The main purpose of BAL is to exclude other processes in the differential, as the BAL findings of RB-ILD are nonspecific [<a href="#rid29">29,41</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>BAL specimens are obtained from areas of radiographic abnormality and sent for total and differential cell counts, microbiologic studies, and cytology. (See  <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage", section on 'Cell counting'</a> and  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a>.)</p><p>The BAL in patients with RB-ILD shows similar cell counts to those of healthy cigarette smokers, such as an increased number of macrophages with golden- (most common), brown-, or black-pigmented inclusions, and proportionately lower percentages of other cellular constituents. Absence of pigmented macrophages is atypical and should lead to consideration of an alternate diagnosis. Neutrophilia and eosinophilia in the BAL fluid are rare in RB-ILD. (See <a class="local">'Histopathology'</a> below.)</p><p>Transbronchial biopsy is obtained during bronchoscopy when technically feasible. As with BAL, the main purpose is to exclude other diseases. A larger biopsy sample than can be obtained with transbronchial biopsy is typically needed to confirm a diagnosis of RB-ILD. Tissue samples are sent for histopathologic and microbiologic analysis. (See  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Transbronchial lung biopsy'</a>.)</p><p class="headingAnchor" id="H344100844"><span class="h2">Surgical lung biopsy</span><span class="headingEndMark"> — </span>Surgical lung biopsy is not always necessary in RB-ILD. If the diagnosis is strongly suspected based on clinical features, pulmonary function test results, and imaging studies, a trial of smoking cessation should precede lung biopsy. In contrast, surgical lung biopsy is typically obtained when the diagnosis remains unclear after the above studies, the patient has moderate to severe respiratory impairment, and does not improve following smoking cessation. Lung biopsy can exclude other ILDs and provide corroborative evidence of RB-ILD [<a href="#rid42">42,43</a>]. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Overview'</a>.)</p><p>Lung biopsy may be obtained via video-assisted thoracoscopic surgery (VATS) or open thoracotomy. Ideally, samples are obtained from more than one lobe, targeting areas of varying severity of radiographic disease, as determined by HRCT. Alternatively, transbronchial cryobiopsy is an emerging technique for lung biopsy, where available. A confident diagnosis of RB-ILD or desquamative interstitial pneumonia by transbronchial cryobiopsy has only been reported in a small number of patients [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Specimen collection'</a> and  <a class="medical medical_review" href="/z/d/html/4407.html" rel="external">"Bronchoscopic cryotechniques in adults", section on 'Cryobiopsy'</a>.)</p><p class="headingAnchor" id="H92410985"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>The classic lesion in RB-ILD is the accumulation of tan-pigmented macrophages (ie, smokers' macrophages) within the lumens of first and second order respiratory bronchioles  (<a class="graphic graphic_table graphicRef73463" href="/z/d/graphic/73463.html" rel="external">table 1</a>) [<a href="#rid5">5,7,9,11,46,47</a>]. These intraluminal macrophages are accompanied by a patchy submucosal and peribronchiolar infiltrate of lymphocytes and histiocytes. The interstitial histiocytes may contain dusty brown cytoplasmic pigment identical to that seen within the intraluminal macrophages, or they may contain coarse black anthracotic pigment [<a href="#rid7">7,47</a>]. The bronchioles may be ectatic and mucus filled. Peribronchiolar fibrosis expands in a stellate fashion into contiguous alveolar septa, which are lined by hyperplastic type II cells and cuboidal bronchiolar-type epithelium  (<a class="graphic graphic_picture graphicRef57687" href="/z/d/graphic/57687.html" rel="external">picture 1</a>). The changes are patchy at low magnification and have a bronchiolocentric distribution. The pulmonary parenchyma away from the airway is usually normal or may demonstrate mild hyperinflation. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Respiratory bronchiolitis-associated ILD'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiating RB and RB-ILD</strong> – It is controversial whether RB-ILD can be differentiated from RB on pathologic grounds. Like RB-ILD, RB is characterized by accumulation of tan- or golden-pigmented "smokers'" macrophages in the bronchiolar lumens and chronic inflammation and fibrosis in membranous and respiratory bronchioles [<a href="#rid9">9,46</a>]. Variable, but generally mild fibrosis is described in the adjacent alveolar walls [<a href="#rid11">11</a>]. The lesions seen in RB-ILD may be more pronounced than the mainly mild clusters of brown-pigmented macrophages in respiratory and membranous bronchioles in otherwise healthy cigarette smokers with RB [<a href="#rid7">7,10</a>]. The more extensive the alveolar wall fibrosis, the more likely that the patient has RB-ILD rather than RB, although the pathologic changes require compatible clinical manifestations for confirmation of RB-ILD [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation from desquamative interstitial pneumonia</strong> – One challenge for the pathologist is to differentiate RB-ILD from desquamative interstitial pneumonia (DIP), another form of idiopathic interstitial pneumonia (IIP) that is strongly associated with cigarette smoking [<a href="#rid3">3,7,13,48</a>]. DIP is characterized by a prominent and diffuse accumulation of intra-alveolar macrophages (that may show fine granular positivity with iron stains), hyperplasia of type II pneumocytes, and mild interstitial chronic inflammation  (<a class="graphic graphic_table graphicRef59081" href="/z/d/graphic/59081.html" rel="external">table 2</a> and <a class="graphic graphic_picture graphicRef58789" href="/z/d/graphic/58789.html" rel="external">picture 2</a>) [<a href="#rid49">49</a>]. A semiquantitative histologic evaluation comparing RB-ILD to DIP disclosed significantly more lymphoid follicles, interstitial fibrosis, and eosinophils in DIP [<a href="#rid3">3</a>]. The main feature that distinguishes DIP from RB-ILD is that DIP affects the lung in a more uniform and diffuse manner, lacking the bronchiolocentric distribution seen in RB-ILD, but there is considerable clinical, radiologic, and histologic overlap between these entities. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Desquamative interstitial pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airspace enlargement with fibrosis</strong> – Airspace enlargement with fibrosis has been identified as a pathologic feature in smokers that may be distinct from RB-ILD and may be difficult to distinguish from usual interstitial pneumonia (UIP) [<a href="#rid12">12,50,51</a>]. A case series described the HRCT imaging features in seven patients with histologically identified airspace enlargement with fibrosis; patchy areas of mild reticulation were noted around predominantly subpleural upper zone emphysematous changes, usually associated with patchy ground-glass opacities [<a href="#rid52">52-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation from dust-related environmental lung disease</strong> – Accumulation of pigmented alveolar macrophages is not entirely specific to cigarette smoking or RB; similar abnormalities have been demonstrated in patients with other conditions  (<a class="graphic graphic_table graphicRef60250" href="/z/d/graphic/60250.html" rel="external">table 3</a>) [<a href="#rid55">55,56</a>]. As an example, pigmented macrophages are noted in dust-related environmental lung disease (eg, pneumoconioses due to asbestos, silica, aluminum oxide, iron oxide). However, while reminiscent of RB, these macrophages lack the characteristic tan pigmentation of the smokers' macrophages of RB and are usually associated with dust nodules. (See  <a class="medical medical_review" href="/z/d/html/4321.html" rel="external">"Silicosis", section on 'Pathology'</a>.)</p><p></p><p class="headingAnchor" id="H2116947317"><span class="h2">Radiographic-histopathologic correlation</span><span class="headingEndMark"> — </span>The correlation between HRCT and histopathologic findings in RB-ILD can aid in diagnosis [<a href="#rid57">57</a>]. In a study of cigarette smokers undergoing lung resection for various pulmonary conditions, preoperative features on HRCT scans were correlated with histologic abnormalities of the small airways and parenchyma in the surgical lung specimens [<a href="#rid58">58</a>]. Parenchymal micronodules on the preoperative computed tomography (CT) scan correlated with the histopathologic presence of bronchiolectasis and peribronchiolar fibrosis [<a href="#rid35">35,58</a>]. Areas of ground-glass attenuation were noted on CT scans from 11 patients and were related to three different histopathologic features:</p><p class="bulletIndent1"><span class="glyph">●</span>The accumulation of pigmented macrophages and mucus in the alveolar spaces, associated with mild interstitial inflammation and/or fibrosis (64 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thickening of the alveolar walls with inflammatory cells, but normal alveolar spaces (27 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of an organizing alveolitis (9 percent)</p><p></p><p>In a separate study of 21 patients with RB-ILD, the extent of ground-glass opacity correlated with the amount of macrophage accumulation in the alveoli and alveolar ducts [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1825692299"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A definitive diagnosis of RB-ILD requires histopathologic confirmation of tan-pigmented macrophages within the lumens of first and second order respiratory bronchioles and exclusion of other interstitial pneumonias in combination with clinical evidence of interstitial lung disease (see <a class="local">'Radiographic-histopathologic correlation'</a> above). However, a clinical diagnosis of RB-ILD is often sufficient and is based upon [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A history of current or recent (within the past six months) cigarette smoking (eg, &gt;30 pack years) with symptomatic and radiographic improvement following cigarette smoking cessation. However, lack of improvement with smoking cessation does not exclude RB-ILD [<a href="#rid29">29,32,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute onset of cough or dyspnea, accompanied by crackles on chest examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary function test findings of a restrictive or mixed obstructive and restrictive pattern and a decreased diffusing capacity for carbon monoxide (DLCO) and/or pulse oxygen desaturation on ambulation. (See <a class="local">'Pulmonary function tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-resolution computed tomography (HRCT) manifestations consistent with RB-ILD, especially upper lung zone patchy ground-glass opacities, or ill-defined centrilobular nodules, and bronchial wall thickening. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="headingAnchor" id="H4295665"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of RB-ILD includes a number of bronchiolar disorders and diffuse parenchymal lung diseases, such as nonspecific interstitial pneumonia (NSIP), idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), pulmonary Langerhans cell histiocytosis, hypersensitivity pneumonitis, and diffuse alveolar hemorrhage  (<a class="graphic graphic_table graphicRef60250" href="/z/d/graphic/60250.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a> and  <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis"</a> and  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSIP and IPF</strong> – The clinical manifestations (eg, subacute onset of cough, dyspnea, and crackles) of NSIP resemble those of RB-ILD, although NSIP is characterized by basilar reticular and ground-glass radiographic changes, rather than the more upper lung zone, centrilobular changes of RB-ILD [<a href="#rid1">1,29</a>]. In addition, the mosaic ground-glass appearance of some cases of RB-ILD is not seen in IPF and the honeycomb change seen in IPF does not occur in RB-ILD [<a href="#rid5">5,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Usual interstitial pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Desquamative interstitial pneumonia</strong> – RB-ILD shares several overlapping clinicopathologic features with DIP, a less common form of idiopathic interstitial pneumonia also associated with smoking, and may represent a spectrum of the same disease process [<a href="#rid3">3,32,37,48,59</a>]. On high-resolution computed tomography (HRCT), the ground-glass opacities of DIP tend to be more diffuse than centrilobular and have a lower lobe predilection. These processes are typically differentiated based on the histopathologic findings. (See <a class="local">'Histopathology'</a> above and  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Desquamative interstitial pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary Langerhans cell histiocytosis</strong> – Pulmonary Langerhans cell histiocytosis (PLCH; also known as eosinophilic granuloma), like RB-ILD, is strongly associated with cigarette smoking. Radiographically, PLCH, like RB-ILD, has ill-defined nodular opacities, but unlike RB-ILD, PLCH typically has upper lung zone cysts and honeycomb change. Areas of RB may be seen on pathologic examination of biopsies from patients with PLCH, but these areas are associated with the other features of PLCH. The key pathologic feature of PLCH is Langerhans cells, which are CD1a stain positive and can often be identified in bronchoalveolar lavage (BAL) samples. (See  <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis", section on 'Lung biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity pneumonitis</strong> – Hypersensitivity pneumonitis can have similar clinical manifestations to RB-ILD, including centrilobular ground-glass nodules on HRCT. However, the histopathology of hypersensitivity pneumonitis is characterized by poorly formed, noncaseating granulomas or a prolific mononuclear cell infiltrate, neither of which are seen in RB-ILD. (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis", section on 'Surgical lung biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interstitial lung diseases</strong> – Other interstitial lung diseases that may have a similar radiographic appearance to RB-ILD (eg, centrilobular nodules) include foreign body granulomatosis, follicular bronchiolitis associated with rheumatic disease, sarcoidosis, berylliosis, and metastatic pulmonary calcification. (See  <a class="medical medical_review" href="/z/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a> and  <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults", section on 'Follicular bronchiolitis'</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4367.html" rel="external">"Chronic beryllium disease (berylliosis)"</a> and  <a class="medical medical_review" href="/z/d/html/117030.html" rel="external">"Calcification and ossification of the lungs", section on 'Metastatic pulmonary calcification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse alveolar hemorrhage</strong> – Diffuse alveolar hemorrhage is characterized by the accumulation of pigmented macrophages, similar to RB-ILD. However, the macrophages in alveolar hemorrhage contain hemosiderin pigment, which forms large, coarse, refractile granules, while the pigment in RB-ILD is more finely distributed and indistinct. Additionally, the pigmented macrophages in alveolar hemorrhage are randomly distributed, whereas the pigmented macrophages in RB-ILD have a bronchiolocentric distribution. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Respiratory bronchiolitis-associated ILD'</a>.)</p><p></p><p class="headingAnchor" id="H956842267"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>The initial management of RB-ILD is largely focused on smoking cessation and supportive care.</p><p class="headingAnchor" id="H92410128"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking cessation is strongly advised for patients with RB-ILD, although data regarding the likelihood of symptomatic and physiologic improvement following smoking cessation are conflicting [<a href="#rid5">5,29,32,41,43</a>]. In a retrospective cohort study of RB-ILD, among the 18 patients who discontinued smoking, less than a third had symptomatic and/or physiologic improvement [<a href="#rid29">29</a>]. On the other hand, data from case reports and small case series suggest that approximately two-thirds of those who quit smoking have clinical improvement [<a href="#rid5">5,7,15,32</a>]. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a> and  <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">"Benefits and consequences of smoking cessation", section on 'Benefits of smoking cessation'</a>.)</p><p>Improvements in the high-resolution computed tomography (HRCT) findings of ground-glass opacities and centrilobular nodules have been reported among five patients with RB-ILD who quit smoking [<a href="#rid41">41</a>]. These radiographic improvements were associated with modest improvements in symptoms and diffusing capacity, but not in spirometry or lung volumes. Based on a cohort of lung cancer subjects with smoking-related interstitial fibrosis, RB may regress following cessation of smoking [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H4294980"><span class="h2">Supportive therapy</span><span class="headingEndMark"> — </span>Supportive care, although not formally examined in RB-ILD, generally includes supplemental oxygen, pulmonary rehabilitation, and vaccination with influenza and pneumococcal vaccines. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p>Some patients with RB-ILD also have a component of chronic obstructive pulmonary disease (COPD) that may respond to specific therapy, such as inhaled anticholinergic agents, beta-agonist bronchodilators, or glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p>Some patients with RB-ILD will meet criteria for lung cancer screening with annual low-dose CT. (See  <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p class="headingAnchor" id="H2315283675"><span class="h1">LACK OF RESPONSE TO INITIAL THERAPY</span><span class="headingEndMark"> — </span>Effective pharmacologic therapy for RB-ILD has not been established. </p><p class="headingAnchor" id="H92410121"><span class="h2">Glucocorticoid therapy</span><span class="headingEndMark"> — </span>For patients who have progressive RB-ILD despite smoking cessation, glucocorticoid therapy is sometimes used, but data supporting its efficacy are conflicting [<a href="#rid29">29,32,33,35</a>]. We typically reserve oral glucocorticoid therapy for patients who have advanced disease or progressive deterioration despite smoking cessation. When initiating oral glucocorticoid therapy, we typically begin with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at 0.5 mg/kg ideal body weight per day up to a maximum of 30 mg/day for one month followed by 20 mg/day for an additional two months, although the optimal dosing has not been formally studied [<a href="#rid61">61</a>].</p><p>When a patient responds or stabilizes with treatment, the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose is gradually tapered, aiming to reach 5 to 10 mg daily or on alternate days, by the end of six to nine months, with attempted cessation after approximately 12 months. Even among patients with an initial response, worsening during tapering or discontinuing glucocorticoids is not uncommon.</p><p>When no apparent improvement is noted after the first three months of treatment, we taper and discontinue glucocorticoids as quickly as possible.</p><p>Glucocorticoid treatment is associated with a variety of side effects. We support ongoing assessment of the risks and benefits of continued steroid use, as well as proactive measures to reduce adverse effects (eg, prevention of bone loss and opportunistic infection). (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Case series of glucocorticoid therapy have yielded mixed results:</p><p class="bulletIndent1"><span class="glyph">●</span>In the retrospective cohort study described above (see <a class="local">'Smoking cessation'</a> above), the 15 patients who were treated with oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> experienced progressive deterioration in pulmonary function over several years, and one patient died of respiratory failure [<a href="#rid29">29</a>]. It is unclear whether the progression of disease on glucocorticoid therapy reflects the initiation of therapy in more advanced or clinically progressing patients, or an adverse effect of the therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study of 12 patients with RB-ILD, of whom 11 received glucocorticoid therapy, initial improvement in symptoms was noted in 6, but over the long term only 3 remained improved, while 8 had disease stabilization, and 1 experienced disease progression [<a href="#rid32">32</a>]. However, only four of the patients successfully quit smoking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of nine patients, who discontinued smoking and took oral glucocorticoid therapy, all had clinical and functional improvement and some had radiographic improvement [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case series, two patients who continued to smoke had progressive disease despite therapy with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> in one patient and prednisone with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> in the other [<a href="#rid33">33</a>]. Subsequently, both improved with smoking cessation while no longer taking immunosuppressive therapy.</p><p></p><p class="headingAnchor" id="H4185062104"><span class="h2">Second-line immunosuppressive agents</span><span class="headingEndMark"> — </span>Only rare use of immunosuppressive therapy has been reported for RB-ILD, generally for patients with advanced disease and without reported success [<a href="#rid15">15,29</a>]. We only add immunosuppressive therapy (eg, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) when a patient has had a response to glucocorticoid therapy and needs a glucocorticoid-sparing agent. When a glucocorticoid-sparing agent is added, we favor azathioprine as it is associated with the least toxicity among the immunosuppressive agents. The use of azathioprine in interstitial lung disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Azathioprine'</a> and  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H4295035"><span class="h2">Lung transplantation</span><span class="headingEndMark"> — </span>Lung transplantation has not been reported for RB-ILD, in particular. The guidelines for lung transplantation for ILD (eg, diffusing capacity [DLCO] &lt;39 percent, oxygen desaturation &lt;88 percent on six-minute walk test, or decrease in forced vital capacity of 10 percent or greater within six months) are discussed separately [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure", section on 'Interstitial lung disease'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Long-term survival is common among patients with RB-ILD [<a href="#rid5">5,7,15,29,32</a>]. However, the clinical course of symptoms, pulmonary function, and radiographic abnormalities is variable:</p><p class="bulletIndent1"><span class="glyph">●</span>Several small case series suggest that RB-ILD has a good prognosis and is often reversible with smoking cessation [<a href="#rid5">5,7,15,32,41</a>]. (See <a class="local">'Smoking cessation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, the retrospective cohort study of 25 patients found symptomatic improvement, stabilization, and deterioration in 28, 44, and 28 percent, respectively [<a href="#rid29">29</a>]. Physiologic improvement occurred in only 10 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with RB-ILD may have a considerable risk for lung cancer [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H843908252"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">"Society guideline links: Interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H344100409"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory bronchiolitis (RB) is an asymptomatic pathologic finding in cigarette smokers that is characterized by accumulation of tan- or yellow-pigmented macrophages in the bronchiolar lumens with associated chronic inflammation and fibrosis extending from respiratory bronchioles to the alveolar walls  (<a class="graphic graphic_table graphicRef73463" href="/z/d/graphic/73463.html" rel="external">table 1</a>). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory bronchiolitis-interstitial lung disease (RB-ILD) is a distinct form of interstitial lung disease (ILD) in which the pathologic changes of RB are associated clinical evidence of ILD (eg, symptoms and abnormalities on chest imaging studies and pulmonary function tests). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The distinction between RB and RB-ILD is largely based on the clinical evidence of ILD, as the histopathologic extent of alveolar wall fibrosis is not an adequate discriminative feature. (See <a class="local">'Definition'</a> above and <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with RB-ILD are typically current or former cigarette smokers who present in their 30s to 50s with subacute symptoms of cough and dyspnea. Fine, bibasilar end-inspiratory crackles are common on chest examination. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-resolution computed tomography (HRCT) findings are nonspecific and include diffuse or patchy ground-glass opacities, centrilobular nodules, and air trapping  (<a class="graphic graphic_diagnosticimage graphicRef82553" href="/z/d/graphic/82553.html" rel="external">image 3</a>). Bronchoscopy with bronchoalveolar lavage (BAL) can help identify compatible findings (ie, tan- or yellow-pigmented macrophages) and exclude alternative diagnoses, such as hypersensitivity pneumonitis. (See <a class="local">'Bronchoscopy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When respiratory impairment is mild, the diagnosis of RB-ILD may be based on strong clinical suspicion and compatible pulmonary function test and HRCT findings. Stabilization or improvement with smoking cessation can obviate the need for invasive studies. For more severe or progressive respiratory impairment despite smoking cessation, lung biopsy is often obtained to confirm the diagnosis and exclude other treatable interstitial lung diseases. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of RB-ILD includes a number of diffuse parenchymal lung diseases, such as idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), pulmonary Langerhans cell histiocytosis, hypersensitivity pneumonitis, and diffuse alveolar hemorrhage. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all patients with a suspected or firm diagnosis of RB-ILD, every effort should be made to facilitate smoking cessation, as a significant portion of patients who stop smoking will have improvement or stabilization of disease. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supportive care for RB-ILD includes pulmonary rehabilitation, vaccination with influenza and pneumococcal vaccines, and supplemental oxygen (if indicated). For patients with a component of chronic obstructive pulmonary disease (COPD), specific therapy, such as inhaled anticholinergic agents, inhaled beta-agonist bronchodilators, or inhaled glucocorticoids, may be of benefit. (See <a class="local">'Supportive therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a new diagnosis of RB-ILD and mild to moderate respiratory impairment, an observation period of three months or longer after smoking cessation is reasonable before initiating pharmacologic therapy (ie, glucocorticoids), as many patients will improve with smoking cessation alone. (See <a class="local">'Smoking cessation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have more advanced disease without improvement after smoking cessation or have progressive deterioration, we suggest a trial of oral glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The usual dose of oral glucocorticoid is the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at 0.5 mg/kg ideal body weight per day up to a maximum of 30 mg/day for one month, followed by 20 mg/day for an additional two months. Subsequent dosing is based on the response to therapy. Alternatively, it is reasonable to continue with supportive care alone, due to the potential side effects of glucocorticoid therapy and the lack of data to suggest benefit. (See <a class="local">'Glucocorticoid therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term survival is common among patients with RB-ILD and almost 50 percent experience disease stabilization. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.</a></li><li><a class="nounderline abstract_t">Fraig M, Shreesha U, Savici D, Katzenstein AL. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am J Surg Pathol 2002; 26:647.</a></li><li><a class="nounderline abstract_t">Craig PJ, Wells AU, Doffman S, et al. Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology 2004; 45:275.</a></li><li><a class="nounderline abstract_t">Wright JL, Lawson LM, Pare PD, et al. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis 1983; 127:474.</a></li><li><a class="nounderline abstract_t">Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis 1987; 135:880.</a></li><li><a class="nounderline abstract_t">Guerry-Force ML, Müller NL, Wright JL, et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis 1987; 135:705.</a></li><li><a class="nounderline abstract_t">Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989; 64:1373.</a></li><li><a class="nounderline abstract_t">King TE Jr, Mortenson RL. Syndromes that mimic idiopathic pulmonary fibrosis. Immunol Allergy Clin North Am 1992; 12:461.</a></li><li><a class="nounderline abstract_t">Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291:755.</a></li><li><a class="nounderline abstract_t">Wells AU, Nicholson AG, Hansell DM. Challenges in pulmonary fibrosis . 4: smoking-induced diffuse interstitial lung diseases. Thorax 2007; 62:904.</a></li><li><a class="nounderline abstract_t">Churg A, Müller NL, Wright JL. Respiratory bronchiolitis/interstitial lung disease: fibrosis, pulmonary function, and evolving concepts. Arch Pathol Lab Med 2010; 134:27.</a></li><li><a class="nounderline abstract_t">Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. Mod Pathol 2006; 19:1474.</a></li><li><a class="nounderline abstract_t">Cottin V, Streichenberger N, Gamondès JP, et al. Respiratory bronchiolitis in smokers with spontaneous pneumothorax. Eur Respir J 1998; 12:702.</a></li><li><a class="nounderline abstract_t">Sangani RG, Deepak V, Ghio AJ, et al. Interstitial lung abnormalities and interstitial lung diseases associated with cigarette smoking in a rural cohort undergoing surgical resection. BMC Pulm Med 2022; 22:172.</a></li><li><a class="nounderline abstract_t">Moon J, du Bois RM, Colby TV, et al. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax 1999; 54:1009.</a></li><li><a class="nounderline abstract_t">Xaubet A, Ancochea J, Morell F, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:64.</a></li><li><a class="nounderline abstract_t">Alhamad EH. Interstitial lung diseases in Saudi Arabia: A single-center study. Ann Thorac Med 2013; 8:33.</a></li><li><a class="nounderline abstract_t">Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103:1122.</a></li><li><a class="nounderline abstract_t">Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199.</a></li><li><a class="nounderline abstract_t">Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19:275.</a></li><li><a class="nounderline abstract_t">Carilli AD, Kotzen LM, Fischer MJ. The chest roentgenogram in smoking females. Am Rev Respir Dis 1973; 107:133.</a></li><li><a class="nounderline abstract_t">Weiss W. Cigarette smoke, asbestos, and small irregular opacities. Am Rev Respir Dis 1984; 130:293.</a></li><li><a class="nounderline abstract_t">Weiss W. Cigarette smoking and small irregular opacities. Br J Ind Med 1991; 48:841.</a></li><li><a class="nounderline abstract_t">Dick JA, Morgan WK, Muir DF, et al. The significance of irregular opacities on the chest roentgenogram. Chest 1992; 102:251.</a></li><li><a class="nounderline abstract_t">Woo OH, Yong HS, Oh YW, et al. Respiratory bronchiolitis-associated interstitial lung disease in a nonsmoker: radiologic and pathologic findings. AJR Am J Roentgenol 2007; 188:W412.</a></li><li><a class="nounderline abstract_t">Sismanlar T, Aslan AT, Turktas H, et al. Respiratory Bronchiolitis-Associated Interstitial Lung Disease in Childhood: New Sequela of Smoking. Pediatrics 2015; 136:e1026.</a></li><li><a class="nounderline abstract_t">Flower M, Nandakumar L, Singh M, et al. Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy. Respirol Case Rep 2017; 5:e00230.</a></li><li><a class="nounderline abstract_t">Portnoy J, Veraldi KL, Schwarz MI, et al. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest 2007; 131:664.</a></li><li><a class="nounderline abstract_t">McWilliams AM, Lake FR. Respiratory bronchiolitis associated interstitial lung disease (RB-ILD) presenting with haemoptysis. Respirology 2000; 5:385.</a></li><li><a class="nounderline abstract_t">Mavridou D, Laws D. Respiratory bronchiolitis associated interstitial lung disease (RB-ILD): a case of an acute presentation. Thorax 2004; 59:910.</a></li><li><a class="nounderline abstract_t">Ryu JH, Myers JL, Capizzi SA, et al. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest 2005; 127:178.</a></li><li><a class="nounderline abstract_t">Sadikot RT, Johnson J, Loyd JE, Christman JW. Respiratory bronchiolitis associated with severe dyspnea, exertional hypoxemia, and clubbing. Chest 2000; 117:282.</a></li><li><a class="nounderline abstract_t">Bogin RM, Niccoli SA, Waldron JA, et al. Respiratory bronchiolitis: Clinical presentation and bronchoalveolar lavage findings. Chest 1988; 94:s21.</a></li><li><a class="nounderline abstract_t">Park JS, Brown KK, Tuder RM, et al. Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr 2002; 26:13.</a></li><li class="breakAll">Lynch DA, Schwarz MI, Heinig MT, et al. Respiratory bronchiolitis: Radiographic assessment. Presented at Society of Thoracic Radiology, 1990.</li><li><a class="nounderline abstract_t">Heyneman LE, Ward S, Lynch DA, et al. Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process? AJR Am J Roentgenol 1999; 173:1617.</a></li><li><a class="nounderline abstract_t">Holt RM, Schmidt RA, Godwin JD, Raghu G. High resolution CT in respiratory bronchiolitis-associated interstitial lung disease. J Comput Assist Tomogr 1993; 17:46.</a></li><li><a class="nounderline abstract_t">Okada F, Ando Y, Yoshitake S, et al. Clinical/pathologic correlations in 553 patients with primary centrilobular findings on high-resolution CT scan of the thorax. Chest 2007; 132:1939.</a></li><li><a class="nounderline abstract_t">Hidalgo A, Franquet T, Giménez A, et al. Smoking-related interstitial lung diseases: radiologic-pathologic correlation. Eur Radiol 2006; 16:2463.</a></li><li><a class="nounderline abstract_t">Nakanishi M, Demura Y, Mizuno S, et al. Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation. Eur Respir J 2007; 29:453.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.</a></li><li><a class="nounderline abstract_t">Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.</a></li><li><a class="nounderline abstract_t">Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014; 9:e86716.</a></li><li><a class="nounderline abstract_t">Bango-Álvarez A, Ariza-Prota M, Torres-Rivas H, et al. Transbronchial cryobiopsy in interstitial lung disease: experience in 106 cases - how to do it. ERJ Open Res 2017; 3.</a></li><li><a class="nounderline abstract_t">Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis 1980; 122:265.</a></li><li><a class="nounderline abstract_t">Colby TV. Bronchiolitis. Pathologic considerations. Am J Clin Pathol 1998; 109:101.</a></li><li><a class="nounderline abstract_t">Bak SH, Lee HY. Overlaps and uncertainties of smoking-related idiopathic interstitial pneumonias. Int J Chron Obstruct Pulmon Dis 2017; 12:3221.</a></li><li><a class="nounderline abstract_t">Myers JL, Katzenstein AL. Beyond a consensus classification for idiopathic interstitial pneumonias: progress and controversies. Histopathology 2009; 54:90.</a></li><li><a class="nounderline abstract_t">Kawabata Y, Hoshi E, Murai K, et al. Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course. Histopathology 2008; 53:707.</a></li><li><a class="nounderline abstract_t">Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 2010; 41:316.</a></li><li><a class="nounderline abstract_t">Reddy TL, Mayo J, Churg A. Respiratory bronchiolitis with fibrosis. High-resolution computed tomography findings and correlation with pathology. Ann Am Thorac Soc 2013; 10:590.</a></li><li><a class="nounderline abstract_t">English C, Churg A, Lam S, Bilawich AM. Respiratory bronchiolitis with fibrosis: prevalence and progression. Ann Am Thorac Soc 2014; 11:1665.</a></li><li><a class="nounderline abstract_t">Churg A, Hall R, Bilawich A. Respiratory bronchiolitis with fibrosis-interstitial lung disease: a new form of smoking-induced interstitial lung disease. Arch Pathol Lab Med 2015; 139:437.</a></li><li><a class="nounderline abstract_t">Churg A, Wright JL. Small airways disease and mineral dust exposure. Pathol Annu 1983; 18 Pt 2:233.</a></li><li><a class="nounderline abstract_t">Churg A, Wright JL. Small-airway lesions in patients exposed to nonasbestos mineral dusts. Hum Pathol 1983; 14:688.</a></li><li><a class="nounderline abstract_t">Caminati A, Cavazza A, Sverzellati N, Harari S. An integrated approach in the diagnosis of smoking-related interstitial lung diseases. Eur Respir Rev 2012; 21:207.</a></li><li><a class="nounderline abstract_t">Remy-Jardin M, Remy J, Gosselin B, et al. Lung parenchymal changes secondary to cigarette smoking: pathologic-CT correlations. Radiology 1993; 186:643.</a></li><li><a class="nounderline abstract_t">Davies G, Wells AU, du Bois RM. Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. Clin Chest Med 2004; 25:717.</a></li><li><a class="nounderline abstract_t">Fabre A, Treacy A, Lavelle LP, et al. Smoking-Related Interstitial Fibrosis: Evidence of Radiologic Regression with Advancing Age and Smoking Cessation. COPD 2017; 14:603.</a></li><li class="breakAll">Vassallo R, Limper AH, Ryu JH. Smoking-Related Interstitial Lung Disease. In: Interstitial Lung Disease, 5th, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT 2011. p.961.</li><li><a class="nounderline abstract_t">O'Beirne S, Counihan IP, Keane MP. Interstitial lung disease and lung transplantation. Semin Respir Crit Care Med 2010; 31:139.</a></li><li><a class="nounderline abstract_t">Scheidl SJ, Kusej M, Flick H, et al. Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry. Respiration 2016; 91:26.</a></li></ol></div><div id="topicVersionRevision">Topic 4319 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979095" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15330806" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6838053" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Morphology of peripheral airways in current smokers and ex-smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565934" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826896" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2593722" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Syndromes that mimic idiopathic pulmonary fibrosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4414996" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pathologic changes in the peripheral airways of young cigarette smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909189" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Challenges in pulmonary fibrosis . 4: smoking-induced diffuse interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20073602" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Respiratory bronchiolitis/interstitial lung disease: fibrosis, pulmonary function, and evolving concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951670" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762803" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Respiratory bronchiolitis in smokers with spontaneous pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35488260" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interstitial lung abnormalities and interstitial lung diseases associated with cigarette smoking in a rural cohort undergoing surgical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10525560" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127977" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Report on the incidence of interstitial lung diseases in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440334" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interstitial lung diseases in Saudi Arabia: A single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16457011" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345567" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epidemiology of interstitial lung diseases in Greece.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445300" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866008" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical significance of histological classification of idiopathic interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4683317" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The chest roentgenogram in smoking females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6380358" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cigarette smoke, asbestos, and small irregular opacities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1772799" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cigarette smoking and small irregular opacities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1623762" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The significance of irregular opacities on the chest roentgenogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449735" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Respiratory bronchiolitis-associated interstitial lung disease in a nonsmoker: radiologic and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347438" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Respiratory Bronchiolitis-Associated Interstitial Lung Disease in Childhood: New Sequela of Smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28392919" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356078" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Respiratory bronchiolitis-interstitial lung disease: long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11192551" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Respiratory bronchiolitis associated interstitial lung disease (RB-ILD) presenting with haemoptysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15454660" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Respiratory bronchiolitis associated interstitial lung disease (RB-ILD): a case of an acute presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653981" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631233" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Respiratory bronchiolitis associated with severe dyspnea, exertional hypoxemia, and clubbing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Respiratory bronchiolitis: Clinical presentation and bronchoalveolar lavage findings</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11801899" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11801899" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584810" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419438" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High resolution CT in respiratory bronchiolitis-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079227" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical/pathologic correlations in 553 patients with primary centrilobular findings on high-resolution CT scan of the thorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16865368" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Smoking-related interstitial lung diseases: radiologic-pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135233" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790668" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586252" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28344982" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transbronchial cryobiopsy in interstitial lung disease: experience in 106 cases - how to do it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7416603" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Morphologic and morphometric effects of prolonged cigarette smoking on the small airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426525" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bronchiolitis. Pathologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29138550" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Overlaps and uncertainties of smoking-related idiopathic interstitial pneumonias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054158" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Beyond a consensus classification for idiopathic interstitial pneumonias: progress and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19102010" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004953" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024643" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Respiratory bronchiolitis with fibrosis. High-resolution computed tomography findings and correlation with pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25549035" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Respiratory bronchiolitis with fibrosis: prevalence and progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25036193" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Respiratory bronchiolitis with fibrosis-interstitial lung disease: a new form of smoking-induced interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6674862" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Small airways disease and mineral dust exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6307854" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Small-airway lesions in patients exposed to nonasbestos mineral dusts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941885" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : An integrated approach in the diagnosis of smoking-related interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8430168" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lung parenchymal changes secondary to cigarette smoking: pathologic-CT correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564017" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29043847" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Smoking-Related Interstitial Fibrosis: Evidence of Radiologic Regression with Advancing Age and Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29043847" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Smoking-Related Interstitial Fibrosis: Evidence of Radiologic Regression with Advancing Age and Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20354927" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Interstitial lung disease and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26656753" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
